Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.

  • Kazuma Murakami
  • Published 2014 in Bioscience, biotechnology, and biochemistry


Amyloid β-protein (Aβ) oligomers, intermediates of Aβ aggregation, cause cognitive impairment and synaptotoxicity in the pathogenesis of Alzheimer's disease (AD). Immunotherapy using anti-Aβ antibody is one of the most promising approaches for AD treatment. However, most clinical trials using conventional sequence-specific antibodies have proceeded with… (More)
DOI: 10.1080/09168451.2014.940275


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics